ATTBF — Abattis Bioceuticals Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro Cap

Annual cashflow statement for Abattis Bioceuticals, fiscal year end - September 30th, CAD millions except per share, conversion factor applied.

	2015 September 30th	2016 September 30th	2017 September 30th	2018 September 30th	2019 September 30th
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-5.57	-2.41	-7.93	-77.7	-3.06
Depreciation
Amortisation
Deferred Taxes
Non-Cash Items	3.45	1.24	6.39	70	3.92
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	0.536	0.309	0.188	-0.712	8.45
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Accounts Payable
Change in Payable / Accrued Expenses
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-1.82	-0.733	-1.22	-8.28	9.41
Capital Expenditures	-0.146	-0.046	-0.431	-0.234	-5.06
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	1.27	0.09	0	-16	-6.46
Acquisition of Business
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	1.12	0.044	-0.431	-16.2	-11.5
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	0.725	0.566	2.14	28.1	0.06
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	0.023	-0.119	0.487	3.54	-2.04